|Class||Name/Company||Approval Dates and Comments|
TPP – Canada issued marketing approval to Draxis Health in June
TPP – Canada approved this monoclonal antibody for marketing in
The US FDA approved a new indication in June 2001, for this antifungal
The US FDA approved this antifungal/corticosteroid cream in May
The US FDA issued a warning to consumers in June 2001, to discontinue use of 13 Chinese herbal products
The US FDA issued a drug warning in June 2001, stating that myelosuppression, including anemia, pancyptopenia
The US FDA granted six additional months of marketing exclusivity to Accutane® (Isotretinoin, Hoffmann
In an article published in Clinical Pharmacology and Therapeutics*, Morii, et al, reported that when
*Clin Pharmacol Ther 68(6):613-6 (2000).
Oncologic Agent Re: Maxamine
The University of Pittsburgh Cancer Institute has reported that the immunomodulating agent Maxamine (histamine dihydrochloride), used in combination with interleukin-2 (IL-2), improved survival for stage IV malignant melanoma patients when compared to those treated with IL-2 alone. Preliminary results also indicated that treatment with Maxamine and IL-2 was safe and well tolerated and had substantially less toxicity than the high-dose regimens of IL-2.
Urticaria Re: Allegra
In June 2000 Aventis Pharmaceuticals announced that Allegra (fexofenadine HCl) 30mg tablets are now available by prescription for the relief of seasonal allergic rhinitis and chronic idiopathic urticaria in children aged 6-11 years. The US FDA approved Allegra for this additional indication in February 2000.